Replication data for: Strategic Formulary Design in Medicare Part D Plans
Principal Investigator(s): View help for Principal Investigator(s) Kurt Lavetti; Kosali Simon
Version: View help for Version V1
| Name | File Type | Size | Last Modified |
|---|---|---|---|
| Pol2016-0248_data | 10/13/2019 05:36:AM | ||
|
|
text/plain | 14.6 KB | 10/13/2019 01:36:AM |
Project Citation:
Lavetti, Kurt, and Simon, Kosali. Replication data for: Strategic Formulary Design in Medicare Part D Plans. Nashville, TN: American Economic Association [publisher], 2018. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-13. https://doi.org/10.3886/E114693V1
Project Description
Summary:
View help for Summary
The design of Medicare Part D causes most beneficiaries to receive fragmented health insurance, with drug and medical coverage separated. Fragmentation is potentially inefficient since separate insurers optimize over only one component of healthcare spending, despite complementarities and substitutabilities between healthcare types. Fragmentation of only some plans can also lead to market distortions due to differential adverse selection, as integrated plans may use drug formularies to induce enrollment by patients that are profitable in the medical insurance market. We study the design of insurance plans in Medicare Part D and find that formularies reflect these two differences in incentives.
Scope of Project
JEL Classification:
View help for JEL Classification
D82 Asymmetric and Private Information; Mechanism Design
G22 Insurance; Insurance Companies; Actuarial Studies
H51 National Government Expenditures and Health
I13 Health Insurance, Public and Private
I18 Health: Government Policy; Regulation; Public Health
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
D82 Asymmetric and Private Information; Mechanism Design
G22 Insurance; Insurance Companies; Actuarial Studies
H51 National Government Expenditures and Health
I13 Health Insurance, Public and Private
I18 Health: Government Policy; Regulation; Public Health
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
Related Publications
Published Versions
Report a Problem
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.